Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

On May3, 2017, Portola Pharmaceuticals, Inc. and Dr.JohnT.
Curnutte, M.D., Ph.D., Portolas Executive Vice President,
Research and Development, entered into an amended and restated
offer letter (the Offer Letter). to the terms of the Offer
Letter, Dr.Curnuttes responsibilities remain the same and his
work hours increased back to 50%. Dr.Curnuttes salary is
reinstated to his prior annual salary rate of $445,571. In
addition, equity incentive awards previously granted to
Dr.Curnutte will remain outstanding and continue to vest in
accordance with their terms, and he remains eligible for an
annual bonus. Portola will also pay Dr.Curnutte $1,800 per month
to continue coverage of his personal retirement medical program.

The foregoing description of the Offer Letter is qualified in its
entirety by reference to the full text of the Offer Letter, which
is filed as Exhibit 10.1 to this Current Report on Form 8-K and
incorporated herein by reference.

Item9.01 Financial Statements and Exhibits

(d)Exhibits

About Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company’s Syk is a mediator of immune response in various types of immune cells. The Company has a program of highly selective Syk inhibitors, one of which is partnered with Ora Inc. Its Betrixaban is an oral once-daily inhibitor of Factor Xa. Its Andexanet alfa, is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor. The Company is developing orally available kinase inhibitors to treat hematologic disorders and inflammation.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Recent Trading Information

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) closed its last trading session down -0.93 at 37.31 with 599,339 shares trading hands.